Clinical trials: Non Alcoholic Fatty Liver
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease
Amlexanox for Type 2 Diabetes and Obesity
This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day.
- Conditions
- Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01842282
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Non-alcoholic Steatohepatitis
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a…
- Trial name
- NCT06716905
- Testing
- ACT500 tablets
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Non-Alcoholic Fatty Liver Disease, Childhood Obesity
Clinical Epidemiology of NAFLD in Children and Adolescents
Background: Non-alcoholic fatty liver disease (NAFLD) is rapidly increasing alongside overweight and obesity, not only in adults but also in children and adolescents.
- Trial name
- LiverKids (NCT05526274)
- Testing
- Vibration-Controlled Transient Elastography (VCTE) with Controlled Attenuation Parameter (CAP)
- Where
- Spain
- Volunteers
- 2,866 people, healthy volunteers welcome
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Hepatic Ischemia-reperfusion Injury, Non-alcoholic Fatty Liver Disease
Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD
To better understand the occurrence of hepatic ischemia-reperfusion injury (IRI) in patients with non-alcoholic fatty liver disease (NAFLD) and the role of macrophage polarization in this process, this study will retrospectively…
- Trial name
- NCT06950710
- Testing
- NAFLD
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Zhifeng Gao
Non-Alcoholic Fatty Liver Disease
Super HEROES: Searching How the Extract Rebaudioside Occludes Excess Steatosis
In order to determine whether rebaudioside consumption can be used as a treatment for adolescents with Non-alcoholic Fatty Liver Disease (NAFLD) by demonstrating a decrease in alanine aminotransferase (ALT) levels participants…
- Trial name
- NCT03985020
- Testing
- Stevia Intervention, Water Intervention
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Los Angeles
Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia
Study of ECC4703 With Sulfasalazine and Pitavastatin
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis.
- Trial name
- NCT07726368
- Testing
- ECC4703, Sulfasalazine, Pitavastatin
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)
Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET
This observational study aims to quantify whole-body amino acid and glucose metabolism in healthy adults and in patients with non-alcoholic fatty liver disease (NAFLD) using total-body PET/CT.
- Trial name
- NCT07366710
- Testing
- 18F-FDG (oral), 18F-FDG (intravenous), 18F-FET (oral)
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Non-Alcoholic Steatohepatitis
BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH
This study's aim is to develop an algorithm for the ¹³C-Octanoate Breath Test with or without the ¹³C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histological findings associated with of Non-Alcoholic…
- Trial name
- NCT02314026
- Testing
- Suspected NASH BreathID test with 13C-Octanoate, Suspected NASH Breath test with 13C Methacetin
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 140 people
- Sponsor
- Meridian Bioscience, Inc.
MAFLD, Fatty Liver
Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)
This RCT investigates the impact of Ganoderma lucidum on antioxidant staus, NRF2 levels and lipid metabolism in individuals with Metabolic Associated Fatty Liver Disease.
- Conditions
- MAFLD, Fatty Liver, Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD, Fatty Liver, Nonalcoholic
- Trial name
- GL-MAFLD-NFR2 (NCT07564947)
- Testing
- Ganoderma lucidum
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- University of Agriculture, Peshawar
Non-Alcoholic Fatty Liver Disease
Effect of Alpha Lipoic Acid on Non-alcoholic Fatty Liver Diseases
In developed counties Non-alcoholic fatty liver disease (NAFLD) becomes the most common cause of chronic liver disease , but its prevalence in developing countries like India is also increasing (10 -20%).Till date, there is no…
- Trial name
- NCT04475276
- Testing
- Alphalipoic acid
- Where
- India
- Volunteers
- 120 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
NAFLD( Non-alcoholic Fatty Liver Disease )
The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine
To investigate in subjects with non-alcoholic fatty liver disease the direct effects of a Chinese herb formula.
- Trial name
- NCT01677325
- Testing
- Chinese herb (YiQiSanJu)
- Volunteers
- 40 people
- Sponsor
- Fudan University
Hepatitis B
Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
Pilot study to assess the antiviral activity and safety of Besifovir dipivoxil 150mg and L-carnitine 660mg compared to Tenofovir Alafenamide 25mg in chronic hepatitis B patients with Nonalcoholic fatty liver
- Trial name
- NCT03604016
- Testing
- Besifovir dipivoxil, L-carnitine, Tenofovir Alafenamide
- Volunteers
- 76 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Non-alcoholic Steatohepatitis
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis
This study aims at evaluating and comparing the protective outcomes of using Obeticholic acid versus Vitamin E in NASH patients without cirrhosis.
- Trial name
- NCT05573204
- Testing
- Obeticholic Acid Oral Tablet, Vit E
- Where
- Egypt
- Volunteers
- 59 people
- Sponsor
- Tanta University
Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
This study is researching an experimental drug called ALN-PNP. This study is focused on participants who are known to have nonalcoholic fatty liver disease (NAFLD), and a specific variant of the patatin-like phospholipase domain…
- Conditions
- Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH), Genetic Risk Factor
- Trial name
- NCT06024408
- Testing
- ALN-PNP
- Where
- 5 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Regeneron Pharmaceuticals
Non-alcoholic Steatohepatitis (NASH)
Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis
The purpose of this study was to assess the safety, tolerability, and efficacy of a combination treatment of tropifexor (LJN452) and cenicriviroc (CVC) in adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis.
- Trial name
- TANDEM (NCT03517540)
- Testing
- Tropifexor (LJN452), Cenicriviroc (CVC)
- Where
- 65 sites in United States, Argentina and 15 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Liver Diseases, Liver Cirrhosis
Non-invasive Ultrasound Diagnosis of Chronic Liver Diseases in Hepatology Consultation
Early screening and monitoring of chronic liver diseases in hepatology practice has become crucial. To achieve this goal, hepatology clinics need simple and available tools at the point-of-care to perform disease severity…
- Conditions
- Liver Diseases, Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
- Trial name
- DIACEPA (NCT04782050)
- Testing
- Ultrasound liver assessment
- Where
- France
- Volunteers
- 100 people
- Sponsor
- E-Scopics
Nonalcoholic Steatohepatitis
Comparative Clinical Study to Evaluate the Efficacy and Safety of Rosuvastatin Vs CoQ10 on Nonalcoholic Steatohepatitis
This study will be a randomized, controlled, parallel study that aims to evaluate the efficacy and safety of Rosuvastatin versus Coenzyme Q10 on nonalcoholic steatohepatitis patients.
- Trial name
- NCT05731596
- Testing
- Rosuvastatin 20 Mg Oral Tablet, Coenzyme Q10 100 MG Oral Capsule
- Volunteers
- 46 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease
The Influence of SARS-CoV-2 Lifestyle Changes on Non-alcoholic Fatty Liver Disease Evolution
Unhealthy lifestyle represents a key element fueling the non-alcoholic fatty liver disease (NAFLD) onset and worsening. The investigators aimed to evaluate the effects of confinement-related lifestyle changes experienced during…
- Trial name
- NCT05416970
- Testing
- SUPERIMPOSED SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2) LIFESTYLE CHANGES
- Where
- Italy
- Volunteers
- 122 people
- Sponsor
- University of Campania Luigi Vanvitelli
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
Effect of Adjustable Intragastric Balloon in Obese Non-alcoholic Fatty Liver Disease
Aims and objectives: The Investigator aimed to evaluate effect of adjustable intra gastric balloon on non-alcoholic fatty liver disease/non alcoholic steatohepatitis (NAFLD/NASH) with or without diabetes mellitus, who have failed…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04182646
- Testing
- Spartz Balloon
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Asian Institute of Gastroenterology, India
Fatty Liver
Nonalcoholic Fatty Liver Disease in Taiwanese Children
Nonalcoholic fatty liver disease (NAFLD) is an emerging and important disease in Taiwan. However, the prevalence and clinical characteristics have not been studied well.
- Trial name
- NCT00274183
- Where
- Taiwan
- Volunteers
- 614 people
- Sponsor
- Far Eastern Memorial Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.